Individual Risk Assessment

Providing the safest, high-quality allografts for transplantation is the goal of all tissue providers. However, as medical advancements in communicable disease control or elimination provide viral load reduction and disease cure, is donor screening and deferment appropriate to these advancements? Now is a time for allograft providers, regulators, and standard setting organizations to reexamine the donor deferral criteria.